Sirnaomics Inc., a Gaithesburg, MD-based biopharmaceutical company focused on the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, raised a $22m Series C2 financing round.
This round was led by CR-CP Life Sciences Fund, with participation from Rich Yield Capital from Shanghai, Rolling Boulder Investment from Shenzhen and Legend Sky Investment of USA.
Therefore, the company has completed its Series C financing combining the previously announced C1 round of $25m and C2 round for a total $47m.
Sirnaomics plans to use the proceeds to support its clinical programs for RNAi therapeutics for treatments of a range of cancers and fibrotic diseases, and to advance its technology platforms.
The company’s lead product candidate (STP705), based on its dual targeting property and early safety study results, is currently being investigated for treatment of non-melanoma skin cancer in a phase II clinical study.
A second clinical trial for treatment of cholangiocarcinoma and hepatocellular carcinoma is expected to commence in the second half of 2019.
Led by Patrick Lu, PhD, President and Chief Executive Officer, Sirnaomics is a biopharmaceutical company advancing RNAi therapeutics, with subsidiaries in Suzhou and Guangzhou.